LanssonPharm is a leading medical innovation company, specializing in the development and industrialization of innovative drugs and high-end formulations. With a team of experts recruited by the National New Drug Evaluation Center and the A Hundred Experts national-level talent training program in Guangdong Province, LanssonPharm is dedicated to advancing breakthrough medications and advanced formulations in the field of central nervous system diseases. Their product portfolio includes innovative drugs for conditions such as depression, schizophrenia, Parkinson's disease, Alzheimer's disease, stroke, and drug addiction.

Collaborating closely with top pharmaceutical research institutions and enterprises in developed countries, LanssonPharm has established various innovative product types and high-end formulation imitations, with multiple proprietary knowledge patents. In 2019, LanssonPharm completed a round of funding and is in the process of establishing a research and development center covering an area of 6,500 square meters. Their vision is to contribute to the globalization of Chinese pharmaceuticals by focusing on the research and development and industrialization of original innovative drugs.

With a strategic focus on both innovative drugs and high-end formulation imitations, LanssonPharm is positioning itself as a pioneer in medical innovation